Taiyo Pacific Partners L.P. Logo


Where others have failed, Taiyo made its mark in the Japanese alternatives space through friendly activism and a deep understanding of the culture.

Download full article


Brian K. Heywood, Chief Executive Officer and Managing Partner of Taiyo Pacific Partners, said, "Japanese pharmaceutical makers have grown sales by 4% annually over the past 10 years, with many more growth opportunities given Japan's aging society. Drug makers themselves, however, face large regulatory risks and heavy burdens from R&D expenses surging 10% per year over the same period. Pharmaceutical companies in Japan face a strong need to outsource this R&D, and the trend is just beginning with only 15% of Japanese drug R&D outsourced vs. 50% in the US. As a leading outsourced research provider in Japan, CMIC is positioned to enjoy the strong growth in pharmaceutical R&D without facing approval risks. We have been impressed by CMIC management's commitment to shareholders and are confident they will continue to create shareholder value."